141 related articles for article (PubMed ID: 16884362)
1. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.
Jandu N; Richardson M; Singh G; Hirte H; Hatton MW
Int J Gynecol Cancer; 2006; 16(4):1536-44. PubMed ID: 16884362
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
[TBL] [Abstract][Full Text] [Related]
3. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Richardson M; Gunawan J; Hatton MW; Seidlitz E; Hirte HW; Singh G
Gynecol Oncol; 2002 Sep; 86(3):279-87. PubMed ID: 12217749
[TBL] [Abstract][Full Text] [Related]
4. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin.
Walker JB; Nesheim ME
J Biol Chem; 1999 Feb; 274(8):5201-12. PubMed ID: 9988770
[TBL] [Abstract][Full Text] [Related]
5. Factors relevant to stimulatory activity of fibrin degradation products in vivo.
Thompson WD; Smith EB; Stirk CM; Stout AJ; Kochhar A
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):517-20. PubMed ID: 1723307
[TBL] [Abstract][Full Text] [Related]
6. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
[TBL] [Abstract][Full Text] [Related]
7. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Hatton MW; Southward SM; Ross BL; Clarke BJ; Singh G; Richardson M
J Lab Clin Med; 2006 Jan; 147(1):27-35. PubMed ID: 16443002
[TBL] [Abstract][Full Text] [Related]
8. Fibrin degradation and angiogenesis: quantitative analysis of the angiogenic response in the chick chorioallantoic membrane.
Thompson WD; Campbell R; Evans T
J Pathol; 1985 Jan; 145(1):27-37. PubMed ID: 2578560
[TBL] [Abstract][Full Text] [Related]
9. Degradation of fibrinogen and fibrin by plasmin and nonplasmin proteases in the chronic subdural hematoma: evaluation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot.
Nomura S; Kashiwagi S; Ito H; Mimura Y; Nakamura K
Electrophoresis; 1993 Dec; 14(12):1318-21. PubMed ID: 8137796
[TBL] [Abstract][Full Text] [Related]
10. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
Wilhelm O; Hafter R; Henschen A; Schmitt M; Graeff H
Blood; 1990 Apr; 75(8):1673-8. PubMed ID: 2139349
[TBL] [Abstract][Full Text] [Related]
11. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis.
Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H
Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409
[TBL] [Abstract][Full Text] [Related]
12. Electrophoretic demonstration of high molecular weight fibrin degradation products persisting in chronic subdural hematomas.
Toyosawa M; Kashiwagi S; Pei W; Fujisawa H; Ito H; Nakamura K
Electrophoresis; 1997 Jan; 18(1):118-21. PubMed ID: 9059832
[TBL] [Abstract][Full Text] [Related]
13. Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test.
Bach-Gansmo ET; Godal HC; Skjønsberg OH
Thromb Res; 1998 Nov; 92(3):125-34. PubMed ID: 9806364
[TBL] [Abstract][Full Text] [Related]
14. Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques.
Stirk CM; Kochhar A; Smith EB; Thompson WD
Atherosclerosis; 1993 Nov; 103(2):159-69. PubMed ID: 7507326
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerotic plaque growth: presence of stimulatory fibrin degradation products.
Thompson WD; Smith EB; Stirk CM; Kochhar A
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):489-93. PubMed ID: 1723306
[TBL] [Abstract][Full Text] [Related]
16. Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen.
Southan C; Thompson E; Panico M; Etienne T; Morris HR; Lane DA
J Biol Chem; 1985 Oct; 260(24):13095-101. PubMed ID: 2932434
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic findings of pleural fluid in dogs and the association between pleural effusions and primary hyperfibrino(geno)lysis: A cohort study of 99 dogs.
Zoia A; Drigo M; Piek CJ; Simioni P; Caldin M
PLoS One; 2018; 13(2):e0192371. PubMed ID: 29462172
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic activity of fibrin degradation products is located in fibrin fragment E.
Thompson WD; Smith EB; Stirk CM; Marshall FI; Stout AJ; Kocchar A
J Pathol; 1992 Sep; 168(1):47-53. PubMed ID: 1280677
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of hemostatic and fibrinolytic markers in dogs with ascites attributable to right-sided congestive heart failure.
Zoia A; Augusto M; Drigo M; Caldin M
J Am Vet Med Assoc; 2012 Nov; 241(10):1336-43. PubMed ID: 23113526
[TBL] [Abstract][Full Text] [Related]
20. Hemostatic Findings in Ascitic Fluid: A Cross-Sectional Study in 70 Dogs.
Zoia A; Drigo M; Piek CJ; Simioni P; Caldin M
J Vet Intern Med; 2017 Jan; 31(1):43-50. PubMed ID: 27862300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
